Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress

被引:261
作者
Waisbren, SE
Albers, S
Amat, S
Ampola, M
Brewster, TG
Demmer, L
Eaton, RB
Greenstein, R
Korson, M
Larson, C
Marsden, D
Msall, M
Naylor, EW
Pueschel, S
Seashore, M
Shih, VE
Levy, HL
机构
[1] Childrens Hosp Boston, Boston, MA 02115 USA
[2] Univ Munster, D-4400 Munster, Germany
[3] Eastern Maine Med Ctr, Bangor, ME USA
[4] Tufts Univ New England Med Ctr, Boston, MA 02111 USA
[5] Maine Med Ctr, Portland, ME 04102 USA
[6] Univ Massachusetts, Sch Med, New England Newborn Screening Program, Jamaica Plain, MA USA
[7] Rhode Isl Hosp, Providence, RI USA
[8] Univ Connecticut, Ctr Hlth, Farmington, CT USA
[9] Pediat Screening Inc, Bridgeville, PA USA
[10] Yale Univ, Sch Med, New Haven, CT USA
[11] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2003年 / 290卷 / 19期
关键词
D O I
10.1001/jama.290.19.2564
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Tandem mass spectrometry now allows newborn screening for more than 20 biochemical genetic disorders. Questions about the effectiveness and risks of expanded newborn screening for biochemical genetic disorders need to be answered prior to its widespread acceptance as a state-mandated program. Objectives To compare newborn identification by expanded screening with clinical identification of biochemical genetic disorders and to assess the impact on families of a false-positive screening result compared with a normal result in the expanded newborn screening program. Design Prospective study involving an inception cohort of newly diagnosed children. Setting Massachusetts, Maine, and a private laboratory in Pennsylvania with expanded newborn screening; other New England states with limited screening. Participants Families of 50 affected children identified through expanded newborn screening (82% of eligible cases); 33 affected children identified clinically (97% of eligible cases); 94 screened children with false-positive results (75% of eligible cases); and 81 screened children with normal results (63% of eligible cases). Main Outcome Measures Child's health and development and the Parental Stress Index. Results Within the first 6 months of life, 28% of children identified by newborn screening compared with 55% of clinically identified children required hospitalization (P=.02). One child identified by newborn screening compared with 8 (42%) identified clinically performed in the range of mental retardation (P<.001). Mothers in the screened group reported lower overall stress on the Parental Stress Index than mothers in the clinically identified group (z=3.38, P<.001). Children with false-positive results compared with children with normal results were twice as likely to experience hospitalization (21% [n=20] vs 10% [n=8], respectively; P=.06). Mothers of children in the false-positive group compared with mothers of children with normal screening results attained higher scores on the Parental Stress Index (z=4.25, P<.001) and the Parent-Child Dysfunction subscale (z=5.30, P<.001). Conclusions Expanded newborn screening may lead to improved health outcomes for affected children and lower stress for their parents. However, false-positive screening results may place families at risk for increased stress and parent-child dysfunction.
引用
收藏
页码:2564 / 2572
页数:9
相关论文
共 39 条
[1]  
Abidin R., 1995, Parent Stress Inventory, V3rd
[2]   New England Consortium: A model for medical evaluation of expanded newborn screening with tandem mass spectrometry [J].
Albers, S ;
Waisbren, SE ;
Ampola, MG ;
Brewster, TG ;
Burke, LW ;
Demmer, LA ;
Filiano, J ;
Greenstein, RMG ;
Ingham, CL ;
Korson, MS ;
Marsden, D ;
Schwartz, RC ;
Seashore, MR ;
Shih, VE ;
Levy, HL .
JOURNAL OF INHERITED METABOLIC DISEASE, 2001, 24 (02) :303-304
[3]   Medium-chain Acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-Based prospective screening of newborns differ from those observed in patients with clinical symptoms: Identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency [J].
Andresen, BS ;
Dobrowolski, SF ;
O'Reilly, L ;
Muenzer, J ;
McCandless, SE ;
Frazier, DM ;
Udvari, S ;
Bross, P ;
Knudsen, I ;
Banas, R ;
Chace, DH ;
Engel, P ;
Naylor, EW ;
Gregersen, N .
AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 68 (06) :1408-1418
[4]  
Atkinson K, 2001, PUBLIC HEALTH REP, V116, P122, DOI 10.1093/phr/116.2.122
[5]  
Bayley N., 1993, Bayley scales of infant and toddler development, VSecond
[6]   Using a nursing framework to measure client satisfaction at a nurse-managed clinic [J].
Bear, M ;
Bowers, C .
PUBLIC HEALTH NURSING, 1998, 15 (01) :50-59
[7]   Mass spectrometry in the clinical laboratory [J].
Chace, DH .
CHEMICAL REVIEWS, 2001, 101 (02) :445-477
[8]   The science and politics of screening newborns. [J].
Cunningham, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (14) :1084-1085
[9]   Tandem mass spectrometry and newborn screening: Pilot data and review [J].
Filiano, JJ ;
Bellimer, SG ;
Kunz, PL .
PEDIATRIC NEUROLOGY, 2002, 26 (03) :201-204
[10]  
GUTHRIE R, 1968, Birth Defects Original Article Series, V4, P92